Novo Nordisk

Novo Nordisk (NYSE:NVO) has reported a remarkable increase in its market value, reaching $500 billion, driven by a surge in demand for its key drugs. What Happened: The Danish pharmaceutical company’s market value soared to $506 billion on Wednesday following the release of its 2023 earnings...

Deutsche Bank has recently conducted a survey suggesting that patients using Novo Nordisk A/S (NYSE:NVO) weight loss medication, Ozempic, may increase their caloric intake after discontinuing the treatment. What Happened: The survey involved 600 U.S. consumers. Seventy percent of the participants ...

What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment. As reported by CNBC, investors initially expressed concerns about these drugs’ market impact. However, with...

Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Danish pharmaceutical company Novo Nordisk (NYSE:NVO) has revised its full-year sales and operating profit outlook. Novo Nordisk is now forecasting a sales growth for 2023 in local currencies of 32% to 38...

Major U.S. stock indices ended in the green on Wednesday, with the Nasdaq Composite marking notable gains of nearly 100 points. The Dow also ended Wednesday’s session in the green, while the S&P 500 experienced a slight uptick. The Nasdaq ended the day 96.83 points higher at 13,659.68,...

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday. The Dow traded up 0.4% to 33,739.30 while the NASDAQ rose 0.58% to 13,562.84. The S&P 500 also rose, gaining 0.52% to 4,358.24. These are the top stocks that gained the attention of...

New side effects of the ‘miracle’ weight loss drug Ozempic are emerging, causing concern among patients and healthcare professionals alike. As reported by Salon, Ozempic, commonly used for weight loss and diabetes management, is coming under scrutiny for potential long-...

Stocks in the food and beverage industry experienced their most challenging week since May 2022, further extending the declines seen in the preceding weeks. The First Trust Nasdaq Food & Beverage ETF (NYSE:FTXG) plummeted by over 5% this week, marking its third consecutive week of losses and...

The CEO of Novo Nordisk (NYSE:NVO), Lars Fruergaard Jorgensen, announced on Friday that the company plans to collaborate with European healthcare systems. The aim is to improve access to its weight-loss drug, Wegovy, for less fortunate and more obese individuals, according to Reuters. “...

Reality TV star, Darcey Silva, is facing accusations of using the ‘miracle’ weight loss drug Ozempic, following her recent post showcasing her significantly slimmer figure, Monsters and Critics reported. Silva and her twin, stars of “Darcey & Stacey,” are currently...

Novo Nordisk’s (NYSE:NVO) popular semaglutide drugs, Wegovy and Ozempic, may unlock three potential new markets, potentially boosting the company’s fortunes, The Motley Fool reported. Over the past year, Novo Nordisk‘s shares have surged 79%, largely due to the success of its...

Novo Nordisk’s weight loss injection, Wegovy, could potentially thwart 1.5 million heart attacks and strokes over 10 years, according to a recent study, reports CNBC. Researchers from the University of California, Irvine discovered that Wegovy could also result in 43...

Comedian Tracy Morgan reveals his weight loss secret is the ‘miracle’ drug Ozempic. As per E! Online, the 54-year-old confessed during an appearance on “Today with Hoda & Jenna”, that the Type-2 diabetes medication has been instrumental in his weight loss...

Weight-loss medications Wegovy and Ozempic may cause life-threatening complications in patients needing surgical procedures, reports Fortune Well. Patients using these drugs may face fatal consequences during surgery or other procedures requiring anesthesia. This is due to the drugs’...

Danish pharma giant Novo Nordisk A/S (NYSE:NVO) reported a strong increase in first-half sales and profits and also hiked its guidance for the full year for the second time this year. What Happened: Novo Nordisk said its net sales for the first half of the year climbed 29% year-over-year to 107.67...